DeciBio

We're excited to kick off the new year with the inaugural Women of Precision Medicine: 25 Perspectives for 2025! This list features 25 exceptional women making an impact as leaders in precision medicine. From women’s health to cancer detection, digital pathology, AI, and beyond, their perspectives address key themes like diagnostic accessibility, equity in genomics, and the promise of multi-omics, emphasizing the transformative contributions of women across the field. This initiative was developed with the contributions of Tina Wang, Katie Maloney, Mané Mikayelyan, Megan Nacar, Kimmi Stacey, and Stephane Budel, whose efforts reflect a shared commitment to amplifying women’s voices and driving meaningful progress in precision medicine. Explore the publication and learn more about how to nominate a WOPM for future initiatives here: https://lnkd.in/gRZxwqFT #WOPM #Leadership #PrecisionMedicine

I was reminded that Exact gained coverage in CRC earlier this month as well, so here is an updated graphic. Exciting to see new MRD providers gaining coverage! SAGA Diagnostics yesterday announced coverage for its tumor-informed dPCR MRD assay Pathlight in stage II-III breast cancer patients, including all subtypes (HR+/HER2-, HER2+, and TNBC), for recurrence monitoring up to 6 years. Early in July, Exact's Oncodetect received Medicare coverage for serial testing in stage II, III and resectable stage IV colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings over a five-year period. And as I've mentioned before, Signatera Genome mirrors pre-existing coverage: The genome-based Signatera MRD assay is covered by Medicare under LCD L38779, including all previously covered Signatera indications (colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monitoring).

Introducing DeciBio’s Precision Medicine in Europe: Policy and Approvals Newsletter As policy momentum accelerates and innovation continues across the continent, we’re launching a new newsletter to track the region's policy shifts, landmark drug approvals, and strategic initiatives. In our July 2025 edition, we highlight just a few of the key developments: • The European Commission’s new "EU Biotech Act" strategy • European Medicines Agency approvals from Merck Group, Roche, and Autolus Therapeutics • Diagnostic wins for Roche and Labcorp • UK momentum: £2B life sciences plan + MHRA/NICE moves for Vertex Pharmaceuticals, Biogen, and Amgen Subscribe now: https://lnkd.in/gKQn7_zp Read the full round-up: https://lnkd.in/gVAecBfn #PrecisionMedicine #LifeSciences #Diagnostics #Oncology #Policy #EMA #MHRA #NICE #EUbiotech #MarketAccess 

What’s next for AI in digital pathology? In our latest Q&A, we spoke with Jill Stefanelli, CEO of Modella AI, about how generative and agentic AI are beginning to reshape oncology R&D, and what hurdles still stand in the way of broad clinical adoption. Just this month, Modella AI announced a multi-year partnership with AstraZeneca focused on accelerating the use of foundation models in oncology, one of several signals that pharma is betting big on AI foundation models to unlock new insights in oncology R&D. Key takeaways from the conversation:  • Generative & agentic AI can streamline workloads and accelerate biomarker discovery.  • Regulatory & reimbursement barriers remain, especially for non-explainable biomarkers, but pairing them with therapy response data could be game-changing.  • Data diversity > data quantity for foundational models, especially in rare indications. AI-based image analysis may offer an edge over traditional computational approaches. At DeciBio, we’re closely following the innovators driving this shift, and how partnerships like this one are moving precision medicine forward. Read the Q&A: https://lnkd.in/g3rwj4aX #DigitalPathology #AIinHealthcare #OncologyInnovation #PrecisionMedicine #FoundationModels #LifeSciences #ModellaAI #AstraZeneca #DeciBioInsights #BiotechNews

New Webinar Alert for CROs, CDx Developers, and Lab Service Providers The pharma services landscape is shifting—macro headwinds are real, but so is the opportunity. Join Andrew Aijian and Hannah Glazier as they unpack key insights from DeciBio’s newly published Pharma R&D Services Market Report (2024–2029). 🔎 What’s covered: • Market trends across discovery, preclinical, and clinical stages • The evolving balance between full-service CROs and niche specialists • Where pharma companies are spending—and where they’re pulling back • Growth projections through 2029, segmented by service area, modality, geography, and more Wednesday, August 13, 2025 9:00 AM - 10:00 AM PT 📍 Zoom Webinar 🔗 Register here: https://lnkd.in/grYV5fVh This session is tailored for leaders across the pharma services ecosystem looking to better understand demand signals and stay competitive. #webinar #industryinsights #biopharma #CROs #CDx

The Pharma R&D services market is projected to reach $129B by 2029, growing at ~5% annually, but the story is more than just the numbers. In our newly released Pharma R&D Services Market Report, we break down the key drivers and moderators shaping this evolving ecosystem. What’s accelerating growth? What’s slowing it down? This new slide helps contextualize how and why the market is moving the way it is. Read the full press release: https://lnkd.in/gEDbfp32 Download the sample report: https://lnkd.in/gnX4qBHq #Pharma #CDMO #CRO #LifeSciencesStrategy #Biopharma #MarketIntelligence #ResearchandDev

What do pharma companies value most in R&D service partners? Our latest report highlights key traits and uncovers gaps that signal real opportunities for innovation. Great work by Hannah Glazier and the team! Check it out 👇 #Pharma #LifeSciences #DeciBioInsights

We’re excited to attend the Association for Diagnostics & Laboratory Medicine (ADLM) Meeting from July 29–30 at McCormick Place. If you’re attending, don’t miss the chance to connect with David Cavanaugh, Co-Founder & Partner at DeciBio, and learn how we support diagnostics, biopharma, and life science tools companies in uncovering growth opportunities and accelerating innovation across clinical and laboratory medicine. 📍 McCormick Place Convention Center 📅 July 29–30, 2025 🔗 Schedule time with David with the link here: https://lnkd.in/eF4brhr6

We’re proud to announce that Carl Schoellhammer, Ph.D. has been named Partner at DeciBio! Carl has been a driving force behind our advanced therapies practice and serves as Managing Director of DeciBio Ventures. His unique blend of scientific expertise, entrepreneurial energy, and strategic thinking has helped shape our work across cell and gene therapies, investment strategy, and beyond. Since joining DeciBio, Carl has continually pushed the boundaries of what’s possible, supporting clients at the forefront of therapeutic innovation and backing early-stage companies advancing the future of precision medicine. Please join us in celebrating this exciting next chapter for Carl and DeciBio! 👏 Check out Carl’s Meet the Team video to hear more about his journey and what’s next. Full press release here: https://lnkd.in/gvQmcMzA #DeciBio #PrecisionMedicine #Leadership #CellTherapy #Biotech #LifeSciences #DeciBioVentures #MeetTheTeam #NextGenLeaders